glp-1 news nov 2025 Pipeline Update: August - Prime Therapeutics Boston, USA. 16th Nov, 2025.

Figure 4: Opportunities Outside of Diabetes and Obesity for Incretin Mimetics As mentioned earlier, NASH is an area that has attracted a high level of manufacturer attention, as the liver disease is associated with metabolic syndrome and represents an area of large commercial opportunity with significant unmet medical need

7 Summary CHD, as a complex cardiovascular disorder, involves multiple factors in its pathogenesis

The post says these results identify contraindications and inform the starting dose, titration pace, and monitoring intervals, and it applies the same expectation to branded and compounded products alike

What is the J-curve and is it real